Drug Reimportation Carries Risk of Counterfeits, PhRMA Says
The Pharmaceutical Research and Manufacturers of America (PhRMA) spoke out against drug reimportation today, citing the worldwide counterfeit threat. The comments appear to come in response to those healthcare reformists seeking legalization of such importation.
“It is critical that we maintain our focus on comprehensive health reform to help all Americans access high-quality and affordable healthcare coverage and services," said PhRMA senior vice president Ken Johnson. "The Congress should not pursue policies that could expose Americans to counterfeit and substandard drug products and potentially weaken the Food and Drug Administration (FDA) and the Department of Homeland Security (DHS) by crippling their ability to fulfill their mission in protecting public health and safety. The worldwide counterfeit threat is knocking at America’s door and will soon be greeted if prescription drug importation proposals move forward."
Johnson says that "public statements by DHS suggest that there has been a significant increase in seizures of counterfeit imports at U.S. borders. For this reason, PhRMA believes that Congress should continue to maintain – not weaken – FDA’s relatively closed drug supply system and also ensure that Customs and Border Protection (CBP) and FDA have the resources to seize potentially dangerous and counterfeit products at our nation’s borders."
For more information on how drug manufacturers can discourage counterfeiting, read our ongoing coverage in Tracking & Tracing Pharmaceutical Products.